Gabapentin Tablet
Product Images NDC 68788-7757

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7757). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 800mg 500tab

Label for Gabapentin Tablets, USP 800 mg from Preferred Pharmaceuticals, Inc. The label states the product is generic for Neurontin and each tablet contains 800 mg of gabapentin. Storage instructions include 20-25°C with excursions permitted to lower temperatures. There are designated areas for package size, expiration date, lot number, batch number, and insurance information. Label includes dosage instructions in both English and Spanish, with a QR code present.*

FDA Label Image

Figure 1 (Image 01)

A line graph depicting mean pain scores over 8 weeks for two groups: placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis shows the mean pain score on a scale from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, showing a decrease in pain scores for the Gabapentin group compared to the placebo group.*

FDA Label Image

Figure 2 (Image 02)

A line graph depicting mean pain scores over 7 weeks during a clinical study comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis shows weeks from baseline through week 7, and the y-axis represents mean pain score. The graph indicates changes during a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Percentages of responders are displayed for placebo vs gabapentin 3600 mg in Study 1 and placebo vs gabapentin 1800 mg and 2400 mg in Study 2, with statistical significance indicated by asterisks.*

FDA Label Image

Cockcroft And Gault Equation (Image 04)

An illustration showing the formula to calculate creatinine clearance (CLCr) based on age in years, weight in kilograms, serum creatinine in mg/dL, and a factor for female patients.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin showing a cyclohexane ring with amino and carboxymethyl side groups attached, representing the active pharmaceutical ingredient gabapentin.*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

A scatter plot comparing differences (in percentage) against daily dose (mg) for Gabapentin from three studies labeled as study a, study b, and study c. The chart shows data points for daily doses ranging from 600 mg to 1800 mg with varying percent differences for each study.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.